PVG Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History

PVG Asset Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	$262K	Buy	+1,101	New	+$253K	0.62%	33

Other funds holding VRTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

PVG Asset Management's VRTX Position: Q1 2020 in Review

PVG Asset Management opened a new position in Vertex Pharmaceuticals (VRTX) in Q1 2020: 1,101 shares worth $262K. The stake represents 0.62% of the portfolio and ranks #33 among its holdings.

856 funds tracked by Wall St. Rank hold VRTX as of Q1 2020.

PVG Asset Management held 1,101 shares of Vertex Pharmaceuticals worth $262K as of Q1 2020.
Vertex Pharmaceuticals was a new PVG Asset Management position in Q1 2020.
Vertex Pharmaceuticals made up 0.62% of PVG Asset Management's portfolio in Q1 2020, its #33 holding.
856 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2020.

Based on PVG Asset Management's 13F filing for Q1 2020, filed 15 May 2020.